UBS Group’s Radiopharm Theranostics RADX Stock Holding History

UBS Group’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.43K	Sell	883 -624	-41%	-$1.75K	﹤0.01%	10258
2026 Q2	$6.31K	Sell	1,507 -1,493	-50%	-$6.64K	﹤0.01%	8843
2026 Q1	$12.9K	Sell	3,000 -11,277	-79%	-$55.1K	﹤0.01%	8236
2025 Q4	$74.5K	Sell	14,277 -3,914	-22%	-$20.8K	﹤0.01%	7044
2025 Q3	$100K	Buy	18,191 +451	+3%	+$2.36K	﹤0.01%	7127
2025 Q2	$82.3K	Buy	+17,740	New	+$79.6K	﹤0.01%	7394
2025 Q1	–	Sell	-1,317	Closed	-$5.91K	–	10921
2024 Q4	$5.91K	Buy	+1,317	New	+$8.66K	﹤0.01%	8611

Other funds holding RADX

PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

UBS Group's RADX Position: Q3 2026 in Review

UBS Group reduced its Radiopharm Theranostics (RADX) stake by 41% in Q3 2026, selling an estimated $1.75K and leaving 883 shares worth $1.43K. The position accounts for ﹤0.01% of the portfolio, ranked #10258.

UBS Group first reported a position in RADX in Q4 2024 and has held it in 7 quarters since. The position peaked at $100K in Q3 2025. 3 funds tracked by Wall St. Rank hold RADX as of Q3 2026.

UBS Group held 883 shares of Radiopharm Theranostics worth $1.43K as of Q3 2026.
UBS Group sold 624 Radiopharm Theranostics shares in Q3 2026, an estimated $1.75K.
Radiopharm Theranostics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10258 holding.
UBS Group first reported a position in Radiopharm Theranostics in Q4 2024 and has held it in 7 quarters since.
UBS Group's Radiopharm Theranostics position peaked at $100K in Q3 2025.
3 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.